Cabaletta Bio, Inc. Common Stock CABA
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:17:03.645Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:04:31.996414653Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T02:17:03.119376+00:00
Cabaletta Bio, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 7.34 | 800.0% | 436.9% | |||
| 30Δ | 6.30 | 800.0% | 365.9% | |||
| 35Δ | 5.27 | 800.0% | 294.9% | |||
| 40Δ | ||||||
| 45Δ | ||||||
| 50Δ | 1.56 | 205.0% | 10.4% | |||
| 55Δ | 1.45 | 208.8% | 12.7% | 1.66 | 218.5% | 9.3% |
| 60Δ | 1.37 | 250.4% | 12.1% | 1.76 | 231.9% | 8.3% |
| 65Δ | 1.28 | 292.0% | 11.5% | 1.87 | 245.4% | 7.2% |
| 70Δ | 1.20 | 333.5% | 10.9% | 1.97 | 258.9% | 6.1% |
| 75Δ | 1.11 | 375.1% | 10.4% | 2.20 | 283.4% | 5.1% |
| 80Δ | 1.03 | 416.6% | 9.8% | 2.48 | 312.3% | 4.2% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 7.34
- IV
- 800.0%
- B/E move
- 436.9%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 6.30
- IV
- 800.0%
- B/E move
- 365.9%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 5.27
- IV
- 800.0%
- B/E move
- 294.9%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.56
- IV
- 205.0%
- B/E move
- 10.4%
55Δ
- Pseudo strike
- 1.45
- IV
- 208.8%
- B/E move
- 12.7%
- Pseudo strike
- 1.66
- IV
- 218.5%
- B/E move
- 9.3%
60Δ
- Pseudo strike
- 1.37
- IV
- 250.4%
- B/E move
- 12.1%
- Pseudo strike
- 1.76
- IV
- 231.9%
- B/E move
- 8.3%
65Δ
- Pseudo strike
- 1.28
- IV
- 292.0%
- B/E move
- 11.5%
- Pseudo strike
- 1.87
- IV
- 245.4%
- B/E move
- 7.2%
70Δ
- Pseudo strike
- 1.20
- IV
- 333.5%
- B/E move
- 10.9%
- Pseudo strike
- 1.97
- IV
- 258.9%
- B/E move
- 6.1%
75Δ
- Pseudo strike
- 1.11
- IV
- 375.1%
- B/E move
- 10.4%
- Pseudo strike
- 2.20
- IV
- 283.4%
- B/E move
- 5.1%
80Δ
- Pseudo strike
- 1.03
- IV
- 416.6%
- B/E move
- 9.8%
- Pseudo strike
- 2.48
- IV
- 312.3%
- B/E move
- 4.2%
Options history
Table
| Date | IV (%) |
|---|---|
| 237.70% | |
| 256.58% | |
| 242.81% | |
| 248.13% | |
| 192.90% | |
| 248.29% | |
| 261.89% |
Biotechnology
CADL
Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform, which uniquely targets…
More →CAI
CAI International, Inc. is a transportation finance company in the United States, Switzerland, France, Korea, Singapore, Rest of Asia, Rest of Europe, and internationally. The…
More →CAPR
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapies for the treatment and prevention of a broad…
More →CBIO
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, is focused on developing candidates for protease products in the fields of hemostasis and complement…
More →CCCC
Description unavailable
More →CDXS
Description unavailable
More →